Georgia Bio Blog

Developing Cell Therapies to Treat the Rarest of Diseases

May 27, 2020

Our next post in the Biotechnology: Beyond Imagination series highlights MaxCyte and the cell therapy technology the company has developed for researchers to accelerate, streamline and improve the drug development process. Beyond Imagination Member Spotlight: MaxCyte About half of the 300 million people who live with a rare disease, like autoimmune disorders and cancers, do not have…

Read More

Beating Covid-19 will change how new therapies are developed

May 27, 2020

The global Covid-19 pandemic has left families and communities around the globe grieving for lost loved ones, exhausted from prolonged social isolation, and anxious about their financial future as unemployment reaches levels not seen since the Great Depression. But it is also driving an unprecedented transformation of the global medical research ecosystem through the search for effective new…

Read More

Race Is On to Create Rapid Covid-19 Tests for the Fall

May 26, 2020

Hundreds of teams are competing a la ‘Shark Tank’ for NIH funding to develop at-home diagnostic strips and other options Even as coronavirus testing ramps up around the country, businesses and public-health authorities seeking to safely reopen are hitting a speed-bump: Standard testing techniques still require sophisticated lab equipment and can take hours or even…

Read More

Merck leaps into Covid-19 vaccine race, aiming to test two different candidates this year

May 26, 2020

Merck, one of the largest vaccine makers in the world, is entering the Covid-19 arena with an announcement on Tuesday it is developing two different vaccines for Covid-19 and is also licensing an oral drug that might treat the virus. Merck is buying Vienna-based Themis, which is developing an experimental Covid-19 vaccine based on a measles…

Read More

COVID-19 Sparks New Opportunities for Digital Health Companies

May 26, 2020

Clinicians and regulators are rethinking how healthcare is provided amid precautions prompted by COVID-19. In-person physician visits don’t fit within the physical distancing guidelines that are now the new normal. New technology presents alternatives. As a digital therapeutics startup, Akili Interactive finds itself thrust in the midst of these changes. The Boston company has developed…

Read More

Philips Wins Regulatory Nod for Clinical Surveillance Biosensor

May 26, 2020

Philips has won a nod from FDA and a CE mark for a next-generation wireless wearable biosensor to help monitor COVID-19 patients in hospital. The Amsterdam, Netherlands-based company touts its next-generation device as being able to enhance clinical surveillance in its patient deterioration detection solution to help clinicians detect risk so they can intervene earlier…

Read More

How rapid can coronavirus tests get?

May 26, 2020

Last week, High Level, a town of approximately 3,000 in northwest Alberta, Canada, received shipments of coronavirus test kits, manufactured by U.S. company Cepheid and Italy’s DiaSorin, from the province’s public health authority. The kits will enable High Level hospitals to deliver COVID-19 test results in as little as 30 minutes.  Before last week, residents of High…

Read More

Novavax launches its first coronavirus vaccine test on humans

May 25, 2020

(Reuters) – U.S. biotech company Novavax Inc has joined the race to test coronavirus vaccine candidates on humans and said it was targeting production of over a billion doses of its vaccine candidate next year. The company, which enrolled its first participants on Monday, said it expected preliminary data on safety and indicators of an…

Read More

Federal Scientists Finally Publish Remdesivir Data

May 23, 2020

Nearly a month after federal scientists claimed that an experimental drug had helped patients severely ill with the coronavirus, the research has been published. The drug, remdesivir, was quickly authorized by the Food and Drug Administration for treatment of coronavirus patients, and hospitals rushed to obtain supplies. But until now, researchers and physicians had not…

Read More